← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › Synthetic anticholinergics, esters with tertiary amino group
oxyphencyclimine
A03AA01
Adult Dosing
- Peptic ulcer disease: 10 mg twice daily (morning and night)
- Maintenance: 5 mg twice daily
- Maximum daily dose: 20 mg
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Adjunctive therapy in the treatment of peptic ulcer disease
- Management of gastrointestinal hypersecretory and hypermotility disorders
Mechanism of Action
- Synthetic anticholinergic/antimuscarinic agent
- Competitively blocks acetylcholine at muscarinic receptors on smooth muscle, secretory cells, and CNS
- Reduces gastric acid secretion and gastrointestinal motility
Contraindications
- Glaucoma (narrow-angle)
- Obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy)
- Obstructive disease of the gastrointestinal tract (achalasia, pyloroduodenal stenosis)
- Paralytic ileus, intestinal atony, or toxic megacolon
- Severe ulcerative colitis or myasthenia gravis
- Known hypersensitivity to oxyphencyclimine or other anticholinergics
Adverse Reactions
- Xerostomia (dry mouth)
- Blurred vision and cycloplegia
- Constipation and urinary retention
- Tachycardia and palpitations
- Drowsiness, dizziness, and headache
- Reduced sweating (anhidrosis) leading to heat intolerance
Drug Interactions
- Amantadine, anti-parkinsonism drugs, and other anticholinergics may potentiate anticholinergic adverse effects
- Antacids may decrease absorption of anticholinergic agents
- Concurrent use with psychotropic medications (phenothiazines, TCAs) may enhance anticholinergic side effects
Curated Content: Needs Vetting Before Put to Clinical Use